# S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

> **NCT00040937** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 147 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** sargramostim
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** melphalan
- **DRUG:** prednisone
- **DRUG:** thalidomide
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00040937
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2008-10
- **Final completion:** 2015-10
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2016-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040937, "S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00040937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*